Back to Results
First PageMeta Content
Health / Macular degeneration / Pharmaceutical sciences / Novartis / Advanced Micro Devices / Pharmaceutical industry / Ranibizumab / Choroidal neovascularization / Medicine / Angiology / Vascular endothelial growth factor


Ophthotech Corporation Enters into Ex-US Licensing and Commercialization Agreement for Fovista® with Novartis - -
Add to Reading List

Document Date: 2014-06-23 10:00:11

Open Document

File Size: 45,04 KB

Share Result on Facebook

City

New York / /

Company

Novartis Pharmaceuticals / Ophthotech Corporation / AMD / /

Country

United States / /

Currency

USD / /

Event

Business Partnership / FDA Phase / Funding / Conference Call / /

IndustryTerm

Web Cast Information / biopharmaceutical / audio web / biotechnology industry / delivery technologies / sciencedriven retinal products / conference call / /

MedicalCondition

disease / macular degeneration / diseases / Age-related macular degeneration / blindness / /

MedicalTreatment

innovative therapies / /

Person

David R. Guyer / /

/

Position

Chief Executive Officer and Chairman of the Board / legal counsel / /

Product

VEGF / Program The Fovista® / Fovista® / /

Technology

biotechnology / delivery technologies / /

URL

www.ophthotech.com / /

SocialTag